Genzyme/Bayer Hope To Fly With Single Campath Phase III Trial In MS
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms will not wait to complete second Phase III study before filing for MS indication, Genzyme says.
You may also be interested in...
No AstraZeneca Cash Takeover; BTG Offers Protherics Stock Deal Instead
Merger valued at $396 million-plus, but widely speculated sepsis partner not the one.
No AstraZeneca Cash Takeover; BTG Offers Protherics Stock Deal Instead
Merger valued at $396 million-plus, but widely speculated sepsis partner not the one.
Genzyme, Isis Retool Mipomersen Deal
Firms confident, but some analysts skeptical about what might be required for approval of lipid antisense drug.